Dr. Rami S. Komrokji

Vice chair of the Malignant Hematology Department and the head of the Leukemia and MDS Section at the Moffitt Cancer Center.

Lifetime Achievement-International Track  

Prof. Komrokji is the Vice Chair of the Malignant Hematology Department and the head of the Leukemia and MDS Section at the Moffitt Cancer Center, Tampa, Florida.


He is a senior member of the Malignant Hematology and Experimental Therapeutics Program at the Moffitt Cancer Center, and Professor in Medicine & Oncologic Sciences at the College of Medicine at the University of South Florida in Tampa, Florida.


After earning a medical degree in 1996 from the Jordan University School of Medicine, Dr. Komrokji completed an internship and residency at Case Western University, St. Vincent Program.  He then completed a fellowship at Strong Memorial Hospital, University of Rochester, in Hematology/Oncology and Hematopoietic Stem Cell Transplantation.


Prof. Komrokji is a world-renowned expert in myeloid neoplasms, a topic on which he has led several clinical trials and lectured worldwide. His work paved the way for FDA approval for luspatercept in myelodysplastic syndromes and pending approval for Pacritinib in myelofibrosis.


He has authored or co-authored more than 275 peer-reviewed manuscripts, 20 book chapters, and more than 700 abstracts in Hematologic Malignancies. He served as a member on the MDS Panel of the National Comprehensive Cancer Network (NCCN) and is currently member of the NIH MDS natural history study steering committee and Aplastic Anemia and MDS Foundation board of directors. He was a member of the editorial board for the Journal of Clinical Oncology (JCO), and is peer reviewer for several medical journals including Blood Journal, JCO and Leukemia Journal.


Prof. Komrokji has won several medical awards nationally and internationally, and was ranked among the top 1% American Cancer doctors for the past 10 years consecutively. He is also among the top 10 MDS specialists worldwide.


Prof. Komrokji’s research interests are in Phase I and II Clinical Trials, and in the outcome research in hematologic malignancies with a focus on myeloid neoplasms. His clinical interests are Myelodysplastic syndromes (MDS), Acute Myeloid Leukemias, and Myeloproliferative neoplasms.